Scientific Study Data

Hedin & Rosberg. Endocrinology, 1983.

Forskolin directly activates adenylyl cyclase, maximally elevates intracellular cAMP, and potentiates PGE2/LH effects non-competitively, establishing its gold-standard cAMP mechanism.

In vitro biochemistry · View on PubMed

Chen et al. (Univ. of Kentucky). Journal of Natural Products, 2009.

Forskolin permeates human skin (flux 0.18 nmol/cm²/h). Whole Coleus forskohlii extract delivered 20× higher flux vs. pure forskolin, confirming enhanced transdermal delivery from native extract.

Ex vivo human skin diffusion · View on PMC

Kang et al. International Journal of Molecular Sciences, 2022.

cAMP elevation in dermal papilla cells (via adenylyl cyclase activation) stimulated DPC proliferation, upregulated VEGF, and extended anagen in mouse model; all effects blocked by PKA inhibitor.

In vitro + in vivo (mouse) · View on PubMed

Kishimoto et al. Genes & Development, 2000.

Wnt/β-catenin (cross-regulated by cAMP/PKA signaling) is the master switch for anagen initiation in follicle bulge stem cells; Wnt agonism reactivates dormant follicles.

In vivo mouse + in vitro · View on PMC

Plume Science. US Patent 11045444 (USPTO), 2021.

Patented composition combining forskolin + ricinoleic acid (C² Complex) for supporting cellular signaling associated with hair follicle activity.

Granted patent · View patent

Tunaru et al. (Max-Planck Institute). PNAS, 2012.

Genome-wide siRNA screen (514 GPCRs) identified EP3 and EP4 prostanoid receptors as ricinoleic acid’s direct targets. Efficacy comparable to PGE2 at EP3/EP4; 12-hydroxy cis configuration required.

In vitro mechanistic · View on PNAS

Colombe et al. Experimental Dermatology, 2008.

EP3 and EP4 receptors are expressed in dermal papilla and outer root sheath cells of anagen human follicles; expression temporally linked to anagen initiation after depilation.

In vitro receptor mapping (human HFs) · View on DOI

Namba et al. Journal of Biological Chemistry, 2001.

EP3C and EP4 receptor subtypes specifically mediate PGE2-induced intracellular cAMP elevation; effect is additive with direct adenylyl cyclase activators (e.g. forskolin).

In vitro receptor biochemistry · View on PubMed

Garza et al. (Perelman/Penn). Science Translational Medicine, 2012.

PGD2 is elevated 3× in bald vs. haired AGA scalp, inhibits hair growth via GPR44/DP2 receptor. PGE2 (mimicked by ricinoleic acid at EP3/EP4) opposes this inhibitory pathway.

Translational · human tissue + mouse · View on PMC

Vanier et al. Experimental Cell Research, 2022.

PGE2 collagen matrix promoted hair follicle anagen entry in mouse model; activated Sox9⁺ and Lgr5⁺ hair follicle stem cell markers, confirming EP receptor signaling drives HFSC activation.

In vivo mouse + in vitro · View on PubMed

Ricinoleic Acid Vasorelaxation Study. European Journal of Pharmaceutical Sciences, 2014.

Ricinoleic acid-derived compounds induced dose-dependent vasorelaxation in rat mesenteric arteries via nitric oxide release, supporting perifollicular circulation improvement.

In vivo / ex vivo vascular · View on PubMed

AROVA Tensile Testing (Plume Science, internal). 2023.

OGP-251 binds to keratin and forms molecular bridges between adjacent strands, reinforcing the keratin fiber network. Tensile testing confirmed increased fiber-to-fiber bonding strength.

Mechanical / material testing · Plume internal report

Fischer et al. (Univ. of Jena). International Journal of Dermatology, 2007.

Caffeine 0.001–0.005% counteracted testosterone-suppressed hair growth in organ culture; stimulated follicle elongation alone. Ki-67 confirmed keratinocyte proliferation.

In vitro (HF organ culture) · View on PubMed

Fischer et al. (Jagiellonian/Jena). British Journal of Dermatology, 2014.

Caffeine prolonged anagen, enhanced IGF-1, suppressed TGF-β2; female follicles showed higher sensitivity. 0.001% extended HF lifespan in culture by ~37%.

In vitro (male & female HFs) · View on PubMed

Dhurat et al. (Mumbai multicenter). Skin Pharmacology & Physiology, 2017.

0.2% caffeine topical liquid was statistically non-inferior to 5% minoxidil (anagen ratio +10.59% vs +11.68%) in 210 men with AGA over 6 months.

RCT · n=210, non-inferiority · View on PubMed

Szendzielorz & Śpiewak (Jagiellonian Univ.). Healthcare (MDPI), 2025.

Systematic review of 9 clinical trials (n=684): topical caffeine is safe and effective against hair loss. Combination formulas showed additive/synergistic benefits.

Systematic Review (9 trials) · View source

Ly et al. Journal of Drugs in Dermatology, 2025.

9 studies reviewed from 587 citations: caffeine is safe and shows promising hair loss reduction across AGA, TE, and AA. Large-scale RCTs needed.

Systematic Review · View on JDD

Caffeine + Adenosine Shampoo RCT. 2024.

0.4% caffeine + 0.2% adenosine shampoo significantly improved hair metrics vs. vehicle control; 71.05% satisfaction in active group. No improvement in control.

RCT · n=76, single-blind · View on PubMed

Trauer et al. (Charité Berlin). Skin Pharmacology & Physiology, 2007.

Caffeine shampoo applied for 2 min detectable in follicles via laser scan microscopy for 24 h post-wash. Transfollicular absorption 10× faster than stratum corneum route.

In vivo human skin / imaging · View on PubMed

Golpour et al. (Iran). Journal of Mazandaran Univ. of Medical Sciences, 2013.

Minoxidil 2.5% + caffeine combination was significantly more effective than minoxidil 2.5% alone in 60 AGA patients over 150 days.

Clinical comparative · n=60 · View on publisher